Los Angeles Capital Management LLC Invests $370,000 in XOMA Royalty Corporation $XOMA

Los Angeles Capital Management LLC purchased a new stake in XOMA Royalty Corporation (NASDAQ:XOMA) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 14,676 shares of the biotechnology company’s stock, valued at approximately $370,000. Los Angeles Capital Management LLC owned approximately 0.12% of XOMA Royalty as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its holdings in shares of XOMA Royalty by 5,087.9% in the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 6,309 shares in the last quarter. Nuveen LLC purchased a new stake in XOMA Royalty in the first quarter valued at $286,000. CM Management LLC boosted its stake in XOMA Royalty by 16.4% in the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock valued at $1,276,000 after acquiring an additional 9,000 shares in the last quarter. Stonepine Capital Management LLC grew its holdings in shares of XOMA Royalty by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after purchasing an additional 4,113 shares during the last quarter. Finally, Woodline Partners LP grew its holdings in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 12,284 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Insider Buying and Selling

In other news, CFO Thomas M. Burns sold 4,330 shares of the firm’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the sale, the chief financial officer owned 30,079 shares in the company, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.10% of the company’s stock.

XOMA Royalty Stock Up 1.2%

XOMA Royalty stock opened at $32.64 on Friday. The stock has a 50 day moving average of $35.80 and a two-hundred day moving average of $30.18. XOMA Royalty Corporation has a twelve month low of $18.35 and a twelve month high of $39.92. The stock has a market capitalization of $394.55 million, a price-to-earnings ratio of -21.06 and a beta of 1.12. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.The company had revenue of $9.35 million for the quarter, compared to analysts’ expectations of $11.47 million. As a group, research analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on XOMA. Wall Street Zen cut XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings upgraded XOMA Royalty from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday. Finally, Zacks Research lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 20th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.50.

XOMA Royalty Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.